Clinical Trial Update: Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessed intrapleural administration of HSV-1716 for malignant pleural mesothelioma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• HSV-1716

Snippet

Sponsor: Virttu Biologics Limited | Conditions: Malignant Pleural Mesothelioma | Phase 1, Phase 2 | Status: COMPLETED